|  |
| --- |
| **Supplementary Table 3. Univariate biomarker analysis in non endometrioid subtype cohort** |
| Variable | Descriptive | RFS | OS |
|  | n (%) | HR (95%CI) | p-value | HR (95%CI) | p-value |
| ER NegativePositiveNE | 26 (74.3)8 (22.9)1 (2.9) | 0.83 (0.23 – 2.94) | 0.76 | 0.61 (0.13 – 2.78) | 0.52 |
| PRNegativePositiveNE | 25 (71.4)9 (25.7)1 (2.9) | 1.07 (0.34 – 3.39) | 0.90 | 0.86 (0.23 – 3.20) | 0.83 |
| ECADNegativePositiveNE | 12 (34.3)18 (51.4)5 (14.3) | 0.49 (0.16 – 1.40) | 0.18 | 0.25 (0.06 – 1.01) | 0.05 |
| HER2NegativePositiveNE | 32 (91.4)2 (5.7)1 (2.9) | 0.60 (0.07 – 4.60) | 0.62 | NE | NE |
| ARID1ANegativePositiveNE | 29 (82.9)6 (17.1)- | 1.44 (0.46 – 4.50) | 0.53 | 1.53 (0.41 – 5.70) | 0.53 |
| PTENNegativePositiveNE | 19 (54.3)15 (42.9)1 (2.9) | 0.53 (0.19 – 1.48) | 0.23 | 0.48 (0.14 – 1.61) | 0.23 |
| L1CAMNegativePositiveNE | 13 (37.1)20 (57.1)2 (5.7) | 0.32 (0.11 – 0.99) | 0.05 | 0.28 (0.0.7 – 1.09) | 0.07 |
| *CTNNB1*Non mutatedMutatedNE | 34 (97.1)1 (2.9) | NE | NE | NE | NE |
| NE: Not evaluable; HR: Hazard ratio; 95%CI: 95% Confidence interval; RFS: Relapse-free survival; OS: Overall survival. |